Investment Thesis
Nature's Sunshine Products exhibits strong fundamentals with excellent gross margins (73.2%), fortress balance sheet, and minimal debt, but is hampered by negative operating cash flow (-$1.8M) and weak capital returns (ROE 3.1%, ROA 2.0%) despite positive earnings. The divergence between flat net income growth and 165% EPS growth indicates aggressive buybacks, masking underlying operational stagnation that must be monitored.
Strengths
- Exceptional gross margin of 73.2% demonstrates strong pricing power in pharmaceutical segment
- Fortress balance sheet with $87.6M cash, $2.1M debt, and 0.01x debt-to-equity ratio
- Excellent liquidity with 2.50x current ratio and 138.3x interest coverage
Risks
- Negative operating cash flow (-$1.8M) and free cash flow (-$4.3M) despite positive earnings signals quality-of-earnings or working capital deterioration
- Abysmal capital returns with ROE of 3.1% and ROA of 2.0% despite healthy margins indicates operational inefficiency
- Flat net income growth (0.0% YoY) and modest revenue growth (5.7%) suggest business maturity or headwinds in core operations
Key Metrics to Watch
- Operating cash flow trend - must return to positive
- Working capital changes - investigate what is driving cash burn
- Segment performance and customer retention in pharmaceutical/direct sales channels
Financial Metrics
Revenue
122.9M
Net Income
5.1M
EPS (Diluted)
$0.29
Free Cash Flow
-4.3M
Total Assets
261.5M
Cash
87.6M
Profitability Ratios
Gross Margin
73.2%
Operating Margin
7.8%
Net Margin
4.2%
ROE
3.1%
ROA
2.0%
FCF Margin
-3.5%
Balance Sheet & Liquidity
Current Ratio
2.50x
Quick Ratio
1.56x
Debt/Equity
0.01x
Debt/Assets
36.2%
Interest Coverage
138.33x
Long-term Debt
2.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:32:34.171716 |
Data as of: 2026-03-31 |
Powered by Claude AI